Literature DB >> 15926617

Anthroposophic vs. conventional therapy of acute respiratory and ear infections: a prospective outcomes study.

Harald J Hamre1, Michael Fischer, Marianne Heger, David Riley, Max Haidvogl, Erik Baars, Eileen Bristol, Michael Evans, Reinhard Schwarz, Helmut Kiene.   

Abstract

CONTEXT: Acute respiratory and ear symptoms are frequently treated with antibiotics. Anthroposophic treatment of these symptoms relies primarily on anthroposophic medications.
OBJECTIVE: To compare anthroposophic treatment to conventional treatment of acute respiratory and ear symptoms regarding clinical outcome, medication use and safety, and patient satisfaction.
DESIGN: Prospective, non-randomised comparison of outcomes in patients self-selected to anthroposophic or conventional therapy under real-world conditions.
SETTING: 29 primary care practices in Austria, Germany, Netherlands, UK, and USA. PARTICIPANTS AND THERAPY: 1016 consecutive outpatients aged > or = 1 month, consulting an anthroposophic (n = 715 A-patients) or conventional physician (n = 301 C-patients) with a chief complaint of acute (< or = 7 days) sore throat, ear pain, sinus pain, runny nose or cough. Patients were treated according to the physician's discretion. PRIMARY OUTCOME: Patients' self-report of treatment outcome (complete recovery/major improvement/slight to moderate improvement/no change/deterioration) at Day 14.
RESULTS: Most common chief complaints were cough (39.9% of A-patients vs. 33.9% of C-patients, p = 0.0772), sore throat (26.3% vs. 23.3%, p=0.3436), and ear pain (20.0% vs. 18.9%, p=0.7302). Baseline chief complaint severity was severe or very severe in 60.5% of A-patients and 53.3% of C-patients (p=0.0444), mean severity (0-4) of complaint-related symptoms was 1.3 +/- 0.7 vs. 1.2 +/- 0.6 (p=0.5197). During the 28-day follow-up antibiotics were prescribed to 5.5% of A-patients and 33.6% of C-patients (p<0.0001), anthroposophic medicines were prescribed to all A-patients and no C-patient. OUTCOMES: Improvement within 24 hours occurred in 30.9% (221/715) of A-patients and 16.6% (50/301) of C-patients (p<0.0001), improvement within 3 days in 73.1% and 57.1% (p<0.0001). At Day 7 complete recovery or major improvement was reported by 77.1% of A-patients and 66.1% of C-patients (p=0.0004), at Day 14 by 89.7% and 84.4% (p=0.0198). Complete recovery rates at Day 7 were 30.5% and 23.3% (p<0.0001); at Day 14 they were 64.2% and 49.5% (p<0.0001). 69.9% of A-patients and 60.5% of C-patients were very satisfied with their physician (p=0.0043); 95.7% and 83.4% would choose the same therapy again for their chief complaint (p<0.0001). After adjustment for country, gender, age, chief complaint, duration of complaint, previous episode of complaint within last year, and baseline symptom severity, odds ratios favoured the A-group for all these outcomes. Adverse drug reactions were reported in 2.7% of A-patients and 6.0% of C-patients (p=0.0157).
CONCLUSION: Compared to conventional treatment, anthroposophic treatment of primary care patients with acute respiratory and ear symptoms had more favourable outcomes, lower antibiotic prescription rates, less adverse drug reactions, and higher patient satisfaction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15926617     DOI: 10.1007/s00508-005-0344-9

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  24 in total

1.  An unrecognized epidemic of Mycoplasma pneumoniae infection in Vienna.

Authors:  Florian Daxboeck; Claudia C Bauer; Ojan Assadian; Gerold Stanek
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

2.  Use and safety of anthroposophic medications in chronic disease: a 2-year prospective analysis.

Authors:  Harald J Hamre; Claudia M Witt; Anja Glockmann; Wilfried Tröger; Stefan N Willich; Helmut Kiene
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  [The Vienna Patient Satisfaction Inventory development of a patient satisfaction instrument for psychiatric outpatient services].

Authors:  Gerlinde Berghofer; Friedrich Schmidl; Stephan Rudas
Journal:  Wien Med Wochenschr       Date:  2006-04

4.  Anthroposophic therapy for attention deficit hyperactivity: a two-year prospective study in outpatients.

Authors:  Harald J Hamre; Claudia M Witt; Gunver S Kienle; Christoph Meinecke; Anja Glockmann; Renatus Ziegler; Stefan N Willich; Helmut Kiene
Journal:  Int J Gen Med       Date:  2010-08-30

5.  Anthroposophic therapy for asthma: A two-year prospective cohort study in routine outpatient settings.

Authors:  Harald J Hamre; Claudia M Witt; Gunver S Kienle; Christof Schnürer; Anja Glockmann; Renatus Ziegler; Stefan N Willich; Helmut Kiene
Journal:  J Asthma Allergy       Date:  2009-11-24

6.  Use and safety of anthroposophic medications for acute respiratory and ear infections: a prospective cohort study.

Authors:  Harald J Hamre; Anja Glockmann; Michael Fischer; David S Riley; Erik Baars; Helmut Kiene
Journal:  Drug Target Insights       Date:  2007-09-14

7.  Outcome of anthroposophic medication therapy in chronic disease: a 12-month prospective cohort study.

Authors:  Harald J Hamre; Claudia M Witt; Anja Glockmann; Renatus Ziegler; Gunver S Kienle; Stefan N Willich; Helmut Kiene
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

8.  Long-term outcomes of anthroposophic treatment for chronic disease: a four-year follow-up analysis of 1510 patients from a prospective observational study in routine outpatient settings.

Authors:  Harald Johan Hamre; Helmut Kiene; Anja Glockmann; Renatus Ziegler; Gunver Sophia Kienle
Journal:  BMC Res Notes       Date:  2013-07-13

9.  Echinacea/sage or chlorhexidine/lidocaine for treating acute sore throats: a randomized double-blind trial.

Authors:  Andreas Schapowal; D Berger; P Klein; A Suter
Journal:  Eur J Med Res       Date:  2009-09-01       Impact factor: 2.175

10.  Eurythmy therapy in chronic disease: a four-year prospective cohort study.

Authors:  Harald J Hamre; Claudia M Witt; Anja Glockmann; Renatus Ziegler; Stefan N Willich; Helmut Kiene
Journal:  BMC Public Health       Date:  2007-04-23       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.